Type I collagen is the most abundant and ubiquitously distributed of the collagen family of proteins. It is a heterotrimer comprising two α1(I) chains and one α2(I) chain which are encoded by the unlinked loci COL1A1 and COL1A2 respectively. Mutations at these loci result primarily in the connective tissue disorders osteogenesis imperfecta and Ehlers-Danlos syndrome types VIIA and VIIB. Two instances of osteoporosis and a single instance of Marfan syndrome are also the result of mutations at these loci. The mutation data are accessible on the world wide web at http://www.le.ac.uk/depts/ge/collagen/collagen.html
INTRODUCTION
The collagens are primary components of the extracellular matrix. They are the most abundant proteins in the human body and are members of a complex superfamily (1) . Some collagen types are ubiquitously expressed, while others have a more limited distribution. Each has a specific function, or set of functions, and there are extensive interactions with other connective tissue components. These interactions combined with the complex nature of collagen biosynthesis (2, 3) result in an exquisitely mutation-sensitive biological system. The clinical phenotypes resulting from collagen mutations are wide-ranging in their manifestations and severity (4) . Of the 19 known vertebrate collagen types, type I is the most abundant and widely expressed collagen in humans. Consequently, it is the best studied and more is known about mutations of type I collagen than any other type.
The basic subunits of collagen are the α-chains which consist predominantly of repeating Gly-Xaa-Yaa tri-peptide motifs. The presence of glycine at every third amino acid is essential to allow the α-chains to adopt the characteristic collagen triple helix. These chains are initially synthesised with N-and C-terminal propeptides which are later enzymatically cleaved. A signal peptide (preceding the N-terminal propeptide) directs the nascent protein to endoplasmic reticulum upon which it is enzymatically removed ( Table 1) . The Xaa and Yaa positions of the tri-peptide repeats are frequently occupied by the imino acids proline and hydroxyproline respectively and there are 338 such tri-peptide repeats in the mature α-chains of type I collagen. The combination of glycines at every third amino acid and the presence of the imino acids allows three collagen α-chains to self assemble into a right-handed triple helix which is stabilised by hydrogen bonding and other charge interactions. The winding of the triple helix initiates by way of interaction of the C-terminal propeptides of the three participating chains and proceeds in a C-to N-terminal direction (2, 3) . Type I collagen is a heterotrimer comprising two α1(I) chains and one α2(I) chain.
THE GENES ENCODING TYPE I COLLAGEN
The α1(I) and α2(I) chains of type I collagen are encoded at the unlinked loci COL1A1 and COL1A2 respectively. COL1A1 is ∼18 kb in size and is located at 17q21.3-q22. COL1A2 is ∼38 kb and is located at 7q21.3-q22.1 (5, 6) .
The most striking feature of these genes is that the exons encoding the triple-helical portions of the collagen chains are mostly 54 bp in length. Those that are not are either twice 54, three times 54, or combinations of 45 and 54 bp exons (Table 2 ). In every instance the exon size is an exact multiple of 9 bp which can encode a Gly-Xaa-Yaa triplet and exons begin with a Gly codon and end with a Yaa position codon. The consequence of this organisation is that exon-skipping mutations maintain the repeating Gly-Xaa-Yaa triplet collagen structure.
THE NUMBERING OF AMINO ACIDS, DNA BASES AND EXONS
For historical reasons the numbering systems used to define the amino acids of the α1(I) and α2(I) chains, and the exons of the genes which encode them, are complicated. This has been a constant source of confusion, especially for those new to the field, and so some discussion of the numbering systems in past and present use is warranted.
Amino acid numbers
Collagen α-chains can be considered to comprise three domains; the N-terminal domain, the collagen domain and the C-terminal domain (Table 1 ). These domains are functional as well as descriptive. Strictly speaking, the α1(I) and α2(I) collagen chains are initially synthesised with signal peptides of 22 amino acids (Table 1) and are known as preproα-chains. Cleavage of the signal peptides produces molecules known as proα-chains which have both N-and C-terminal propeptides (Table 1) . Once the proα-chains have assembled into the characteristic collagen triple helix, they are secreted into the extracellular space where the propeptides are cleaved off by specific proteases. The cleavage process leaves telopeptides flanking the extended triple-helical collagen region at each end of both chains ( Table 1 ). The individual chains of fully processed collagen molecules are known as α-chains. By convention, amino acid 1 is the first glycine of the first Gly-X-Y repeat of the α-chains rather than of the first amino acid of the primary translation products, of the proα-chains, or of the mature α-chains. In practice, this has rarely led to any confusion in spite of there being no formalised numbering system for the signal peptides, N-propeptides or the N-telopeptides. However, a potential source of confusion lies in the numbering of the amino acids of the C-propeptides. Formally, the conventional numbering system ends at 1014, the last amino acid of the triple-helical region. In practice, it is convenient to directly continue the numbering such that the C-telopeptide comprises amino acids 1015-1040 in the α1(I) chain and 1015-1029 in the α2(I) chain. Similarly, the C-propeptides comprise amino acids 1041-1286 and 1030-1276 respectively for the two chains. It should be noted that this numbering practice is by no means universal and many reports of C-propeptide mutations use a numbering system that starts at the first amino acid of the C-propeptide.
Exon numbers
When human collagen cDNAs were first isolated, they represented sequences predominantly from the 3′-ends of the mRNAs. When the first genomic clones were isolated, using these cDNAs as probes, they consequently represented the 3′-end of the gene. Not knowing the full exon/intron structure of the genes, investigators decided initially to number the exons from the 3′-end of the genes. It was only when the entire gene structures were elucidated that the exons were then re-numbered in the conventional 5′ to 3′ direction. This lead to instances of mutations being reported using the reverse-order system (7, 8) . Eventually, it emerged that COL1A1 consisted of 51 exons and COL1A2 of 52 and, for a short time, this lead to further confusion. Amino acids 568-603 are encoded by a single exon of 108 bp in COL1A1, but by two exons each of 54 bp in COL1A2. These two exons of COL1A2 are exons 33 and 34 and initially the single analogous exon in COL1A1 was numbered exon 33. However, it was soon realised that such a numbering system would lead to confusion when discussing analogous exons encoding amino acids C-terminal to position 603. For this reason, the 108 bp exon of COL1A1 encoding amino acids 568-603 of the α1(I) chain is now designated exon '33/34' ( Table 2 ). An example of this exon-numbering confusion is illustrated in the reporting of a 9 bp deletion in COL1A1 (9) which is described as being in exon 43 when, in fact, it is in exon 44 using the present numbering system. 
DNA sequence numbers
Although the entire genomic sequence of COL1A1 is known (10,11) the same is not true for COL1A2. For this reason, a numbering system based on cDNA sequences has been adopted. 'Contig' cDNA sequences were assembled from the complete, but fragmented, data available in the EMBL DNA sequence database. The contigs for the α1(I) and α2(I) cDNAs have been assigned the accession numbers Z74615 and Z74616 respectively. The reporting of all mutation data is based on these sequences. Mutations in intron donor or acceptor sequences, leading to exon skipping, are reported relative to the start or end of the intron (e.g. G +1 →A or A -2 →T).
HOW TYPE I COLLAGEN MUTATIONS LEAD TO DEFECTIVE COLLAGEN AND PRODUCE DISEASE PHENOTYPES
The vast majority of mutations of type I collagen result in the connective tissue disorder osteogenesis imperfecta (OI) (12, 13) which is also known as brittle bone disease. OI may be subdivided into four types that are defined according to clinical phenotype (14) . Type I is the mildest and is inherited in an autosomal dominant manner. Types II, III and IV are more severe and generally arise as new dominant mutations. As a general principle, in type I OI the type I collagen is normal but is produced in reduced amounts. OI types II, III and IV result from the production of abnormal type I collagen due to the incorporation of one or more individually abnormal α-chains. Such abnormalities can include the substitution of amino acids or the shortening or lengthening of α-chains due to exon-skipping mutations or more complex gene rearrangements. Mutations that result in premature chain termination, such that no C-terminal propeptide is produced, result in type I OI as the shortened α-chains do not participate in triple helix formation. The mechanisms of phenotype production have been well reviewed in recent years (4,13,15,16) though a truly satisfactory unifying model of the genotype/phenotype relationship is yet to be proposed. Although type I collagen gene mutations are overwhelmingly dominant in their action, there is a single example of a recessively-inherited case of OI (7). However, evidence suggests that the most cases of recessively-inherited OI type III do not directly involve type I collagen and map to loci other than COL1A1 and COL1A2 (17) .
Apart from OI, there is one other common connective tissue disorder that results from type I collagen gene mutations. Ehlers-Danlos syndrome types VIIA and VIIB are members of a diverse group of connective tissue disorders (18) and result from mutations in COL1A1 and COL1A2 respectively. They share a common basis in that in both instances the cause is the skipping of exon 6 due to mutations in the splice sites at one end or other of the exon. The consequence of the skipping of exon 6 is loss of the site for the cleavage of the N-terminal propeptide which is hence retained. Mutations resulting in the skipping of exon 6 appear to be a much more frequent in COL1A2 than in COL1A1.
MUTATIONS OF COL1A1 AND COL1A2
The first account of a type I collagen gene mutation was of a 0.5 kb deletion in COL1A1 leading to osteogenesis imperfecta type Table 6 . Polymorphisms in COl1A1 cDNA II (19) . This was later characterised more precisely as a deletion of three exons (8, 20) .
Subsequently, however, it has emerged that deletions are a relatively infrequent type of mutation in type I collagen genes. By far the most common type of mutation in COL1A1 and COL1A2 are single base changes causing substitutions of glycines which are essential for correct folding of the collagen triple helix. Such single base substitutions can result in a glycine being replaced by alanine, arginine, aspartic acid, cysteine, glutamic acid, serine or valine and each has been recognised in both type I collagen α-chains. It is also possible to mutate glycines encoded by GGA to the TGA stop codon by a single base substitution though no examples have yet been detected. Interestingly, the two known examples of premature stop codons caused by single base substitutions have both been the result of mutations in CGA arginine codons rather than the expected glycine codon. Finally, it is worth noting that amino acid substitutions in type I collagen genes have been noted in two cases of osteoporosis and in a single atypical case of Marfan syndrome (21) . The amino acid substitutions in COL1A1 and COL1A2 are listed in Tables 3 and 7 .
Exon skipping is a fairly common mutation type resulting mainly from alterations to splice donor sites (Tables 4 and 8 ). Large and small alterations to the gene structure are a final heterogeneous group of mutations (Tables 5 and 9 ).
In the vast majority of instances, the mutations listed below are 'private'-they have only been recorded in a single individual or within a single family. Where a mutation has been reported to have occurred more than once, each individual report is listed in the tables. This is of value especially where the resulting phenotype has been different, perhaps due to differences in the genetic background on which the primary mutation is expressed. Table 8 . Exon skipping mutations in COL1A2 Table 9 . Deletions, insertions, duplications and frameshifts in COL1A2
POLYMORPHISMS OF COL1A1 AND COL1A2 CODING REGIONS
There are several reported polymorphisms in the coding regions of COL1A1 (Table 6 ) and COL1A2 (Table 10 ) though few are either well characterised or frequent enough to be useful as genetic markers. Such markers might be useful in the analysis of the expression of individual alleles. In COL1A1 the potentially useful markers include a sequence polymorphism in the 3′ untranslated region (22) and amino acid 897 of the triple-helical domain can be either alanine or threonine (23) . In COL1A2 there are silent base substitutions in the codons for amino acid 82 of the primary translation product (24) and amino acids 392 and 955 of the triple-helical domain (24, 25) .
ACCESSING THE DATA
The type I collagen mutation data may be accessed on the University of Leicester web server at http://www.le.ac.uk/depts/ ge/collagen/collagen.html . At present, the data are in simple static lists but it is hoped that data will be made available at some time in a more comprehensive manner in a relational database that can be queried from a web page. If you make use of the data from the web server, please cite this article in any materials which you prepare for publication.
